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Congenital lower urinary-tract obstruction (LUTO) is caused by anatomical blockage of the bladder outflow tract or by functional
impairment of urinary voiding. About three out of 10,000 pregnancies are affected. Although several monogenic causes of func-
tional obstruction have been defined, it is unknown whether congenital LUTO caused by anatomical blockage has a monogenic
cause. Exome sequencing in a family with four affected individuals with anatomical blockage of the urethra identified a rare
nonsense variant (c.2557C>T [p.Arg853*]) in BNC2, encoding basonuclin 2, tracking with LUTO over three generations. Re-
sequencing BNC2 in 697 individuals with LUTO revealed three further independent missense variants in three unrelated families.
In human and mouse embryogenesis, basonuclin 2 was detected in lower urinary-tract rudiments. In zebrafish embryos, bnc2
was expressed in the pronephric duct and cloaca, analogs of the mammalian lower urinary tract. Experimental knockdown of
Bnc2 in zebrafish caused pronephric-outlet obstruction and cloacal dilatation, phenocopying human congenital LUTO. Collectively,
these results support the conclusion that variants in BNC2 are strongly implicated in LUTO etiology as a result of anatomical
blockage.
Congenital lower urinary-tract obstruction (LUTO) gener-
ally manifests as urinary bladder outflow obstruction,
which can represent an anatomical blockage or a func-
tional obstruction. LUTO of any kind has an estimated
birth prevalence of three per 10,000 pregnancies.1 The
largest population-based study from the West Midlands
Congenital Anomaly Register in the UK suggests a signifi-
cantly higher prevalence among black andminority ethnic
groups than among white Europeans.1
Little is known about the genetic causes of anatomical
LUTO. Single cases in the literature are associated with tri-
somy 21 or chromosomal aberrations, but for the majority
of cases, theoriginof isolated anatomical LUTOremainsun-
known. Functional LUTO has been extensively genetically
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Table 1. Heterozygous Variants of BNC2 in Families With LUTO
Family Family 1 Family 2 Family 3 Family 4 Family 5
Individual IV-2 III-4 III-2 II-4 III-1 II-1 I-1 II-1 I-1 II-1 II-1
Sex male female female female male male female male male male male
Phenotype distal urethral
stenosis, BL
VUR grade 5
urethral stenosis,
urinary tract
infections,
pollakisuria with
nycturia
meatal urethral
stenosis, bladder
descensus,
pollakisuria with
nycturia, urinary
incontinence
urethral
stenosis
PUV, Rt VUR grade 5,
BL renal hypodysplasia
pathological
voiding on
uroflowmetry
normal RUS
and renal
function
PUV, VUR grade
1-2.5, bladder
diverticles
NA PUV, right
hydonephrosis,left
VUR grade 1,
incontinence until
6 years
PUV, VUR, ESRD
Age of clinical
onset
13 weeks of
gestation
12 years 47 years 42 years
at surgical
correction
prenatal 38 years at
finding of
pathological
uroflowmetry
NA 7 years NA 8 years 11 years
Nucleotide
change
c.2557C>T c.2663A>G c.473C>T c.1036G>C c.13G>A
Transcript ENST00000418777 ENST00000380672 ENST00000380672 ENST00000380672 ENST00000545497
RefSeq GenBank: NM_001317939.1 GenBank: NM_017637.6 GenBank:
NM_017637.6
GenBank:
NM_017637.6
NA
State heterozygous heterozygous heterozygous heterozygous heterozygous
Chr. Pos.
(GRCh37/hg19)
chr9: 16435054 chr9: 16419624 chr9: 16552724 chr9: 16437156 chr9: 16832274
Aminoacid
change
p.Arg853* p.His888Arg p.Thr158Ile p.Glu346Gln p.Val5Ile
Conserved to NA drosophila melanogaster danio rerio danio rerio pongo albelii
Protein domain not known c2h2 zinc finger domain not known not known not known
GERP score NA 5.59 5.84 5.96 -0.728
PPH (score) NA probably damaging (0.981) possibly damaging
(0.878)
benign (0.037) benign (0.015)
SIFT (score) NA deleterious (0) deleterious (0) deleterious (0) tolerated (0.59)
CADD score 19.09 25.7 26.6 22.1 1.466
ACMG pathogenic pathogenic uncertain
significance
uncertain
significance
benign
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defined, e.g., variants of CHRM3 (MIM: 118494) in prune-
belly syndrome,2 variants of HPSE2 (MIM: 613469) and
LRIG2 (MIM: 608869) in urofacial syndrome,3,4 and
variants of MYH11 (MIM: 160745) and ACTG2 (MIM:
102545) in microcolon megabladder hypoperistalsis
syndrome.5,6 Anatomical congenital LUTO can also be fa-
milial, albeit with interfamilial phenotypic variability,
even between identical twins.7–9 Severe forms of LUTO are
usually diagnosed prenatally on the basis of a distended
bladder that fails to empty with dilatation of the upper uri-
nary tract. However, milder forms manifest postnatally,
often with recurrent urinary tract infections (UTI).10 Severe
forms cause oligohydramnios and are associated with
dysplastic kidney malformations that can be secondary
to LUTO.11 This can be deduced because similar kidney dis-
ease occurs in ovine fetuses with surgically generated
LUTO.12 Indeed, LUTOs are the leading cause for end-stage
renal disease (ESRD) in children.13 The most common
anatomical causes of LUTO are posterior urethral valves
(PUVs) at the level of the prostatic urethra, a lesion
unique to males.14 Less common are anterior urethral
valves, also called urethral atresia, that can occur in either
sex.11,15
Here, we present evidence that monoallelic variants in
BNC2, coding for basonuclin 2, are strongly implicated in
isolated anatomical LUTO.
The study was conducted in adherence to the Declara-
tion of Helsinki. The respective informed consent was ob-
tained from the affected individuals or by proxies in the
case of minors. The study was approved by the ethics com-
mittee of the medical faculty of the University of Bonn
(No. 146/12) as well as by the respective ethics
committees of the collaborating centers in Boston, Man-
chester, and Nijmegen (AGORA data and biobank).
Human embryonic material, collected with maternal con-
sent and ethical approval (REC 08/H0906/21þ5), was
sourced from the MRC-Wellcome Trust Human Develop-
mental Biology Resource. Zebrafish and mice were kept ac-
cording to national law and to general recommendations
in our fish facility in Bonn, Germany and the mouse facil-
ity in Frankfurt, Germany, respectively.
We used exome sequencing in a previously unreported
family (family 1; for a detailed description, see Supple-
mental Data and Table 1) whose affected members
had autosomal-dominant LUTO of variable phenotypic
expression (Figure 1C). The male index individual (IV-2)
received vesicoamniotic shunting at 13 weeks of gestation
as a result of early diagnosis of severe LUTO. Postnatally he
was diagnosed with high-grade urethral stenosis. His
mother (III-4) was diagnosed with urethral stenosis at
the age of 16. Prior to her pregnancy with the index indi-
vidual, she had two spontaneous abortions of unknown
cause (Figure 1C). The maternal grandmother (II-4) was
diagnosed with distal urethral stenosis (meatal stenosis)
at the age of 47. Her sister (II-2) denied having voiding
dysfunction but did not consent to any urological or ge-
netic assessment. In accordance with the previouslyTa
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Figure 1. Exome Sequencing and Targeted Re-sequencing in Families with LUTO Phenotype Identifies Variants in BNC2
(A and B) Exon structures of BNC2 cDNA of the two affected transcripts, ENST00000418777 and ENST00000380672, and protein domain
structures are depicted. Positions of mutated nucleotides are indicated by arrows, and respective chromatograms are shown below.
Evolutionary conservation among ortholog proteins is shown for family 2, carrying the p.His888Arg missense variant. The
mutated amino acid residue is indicated with arrowheads and a red box. C2H2 ¼ zinc-finger domain of the Cys2His2 folding group;
C. elegans ¼ Caenorhabditis elegans and D. melanogaster ¼ Drosophila melanogaster.
(legend continued on next page)
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described, well-noted, high within-family phenotypic
variability, we considered her to be healthy. The female
maternal cousin of the index individuals’ mother (III-2)
was diagnosed with high-grade urethral stenosis at the
age of 42.
Exome sequencing was performed on the affected indi-
viduals, II-4, III-2, and IV-2 from family 1 (Figure 1C).
According to recent reports on rare dominantly inherited
congenital anomalies of the kidney and urinary tract
(CAKUT), we considered only variants with an allele fre-
quency <0.0001.16,17 According to these filter criteria, we
detected 11missense and two nonsense variants that segre-
gated in the family (TableS1).All variantswere confirmedby
Sanger sequencing. Among these variants, we prioritized
the two nonsense variants as the most likely to be disease
causing. One variant was found to be a novel p.Trp3* in
ALB (MIM: 103600), encoding albumin. Recessive trun-
cating variants in ALB have been described to cause analbu-
minaemia (MIM: 616000), whereas heterozygous variants
in ALB can cause dysalbuminemic hyperthyroxinemia
(MIM: 615999). Neither condition is associated with
LUTO, and therefore the variant was not considered to
be causative for the LUTOphenotype in the family. The sec-
ond truncating variant, p.Arg853* rs1350162888 (ClinVar:
SCV000891778) (total 860 amino acids) (Table 1), was
found in BNC2 (MIM: 608669, GenBank: NM_001317939,
ENST00000418777) (Figure 1A), which is a candidate gene
for human hypospadias and encodes basonuclin 2, a zinc-
finger-containing protein.18,19 Little is known about the
function of BNC2. Previously, Vanhoutteghem et al. re-
ported on the localization of BNC2 in nuclear speckles
and its potential involvement in nuclear processing of
mRNA.20 Bhoj et al. analyzed Bnc2 expression in the penis
and urethra of Bnc2þ/ and Bnc2/ newborn mice and
determined that Bnc2 expression is highest in the phallic
periurethral tissue,18 consistent with BNC2 having an
important role in urethral development. They further
suggested that BNC2 acts locally in urethral development
in both sexes. The variant in BNC2 has been reported five
times heterozygously in 175,684 alleles in the gnomAD
database (version 2.0.2, date of inquiry 2018/09/20 for all
mentioned gnomAD inquiries) (allele frequency 0.000028,
rs1350162888). Notably, all of the heterozygous carriers
were females.
We next re-sequenced all 14 BNC2 transcripts in 697
individuals with LUTO from the AGORA study in the
Netherlands and from pediatric nephrology departments
in Germany, Poland, the UK, and the US. 13 of the 14
transcripts are predicted to be protein coding. The
protein product for the two transcripts has been verified
in humans so far (ENST00000380672, GenBank: NM_
017637.6, canonical transcript; and ENST00000418777,
GenBank: NM_001317939.1). In total, all rare missense
or nonsense variants identified in this study were found
in one of these two verified proteins except that one
variant was identified in ENST00000545497. All variants
identified in the canonical transcript ENST00000380672
are also contained by the alternatively spliced transcript
ENST00000418777, in which the variant of family 1
was identified. By re-sequencing, we detected one novel
(c.2663A>G [p.His888Arg], ENST00000380672, ClinVar:
SCV000854630) and three rare missense variants
(c.13G>A [p.Val5Ile], ENST00000545497, rs750936655,
allele frequency 0.000048) (c.473C>T [p.Thr158Ile],
ENST00000380672, rs144242525, allele frequency
0.000012) (c.1036G>C [p.Glu346Gln], ENST00000380672,
rs945575406, allele frequency 0.000004) in four indepen-
dent individuals with LUTO (Table 1, Figure S2). The novel
variant c.2663A>G, detected in an individual with PUV
and severe secondary dilatation of his upper urinary tract
(III-1, family 2, Figure 1E), was inherited from an affected fa-
ther (II-1) who had a pathological uroflowmetry (Figure S1).
His renal ultrasound and renal function were normal.
Investigation of the paternal grandparents (I-1 and I-2)
showed that the variant was inherited from the healthy
grandmotherwhodidnothaveanyhistoryofUTI,pollakisu-
ria, or nycturia and who had normal kidneys on renal
ultrasound and normal uroflowmetry. The amino acid
change p.His888Arg is highly conserved to D. melanogaster
(GERP 5.59). Three in silico prediction programs classify
the amino acid change as potentially disease causing and
(according to the American College of Medical Genetics
[ACMG] guidelines) as pathogenic (Table 1). The variant
(c.2663A>G [p.His888Arg], ENST00000380672) is located
in the fourth C2H2 zinc finger domain (Figure 1B). Accord-
ing to SwissProt entry Q6ZN30 and PROSITE, this variant is
located near the second (residues 833–856) of three C2H2
zinc finger domains in BNC2 protein. However, InterPro
and SMART include residue His888 in their signature
matches (residues 833–856 and 861–888) for zinc-finger do-
mains of the C2H2-type. These predictions suggest that this
zincfinger’s very lasthistidine,which is replacedbyarginine,
(C) Pedigree with multiple affected individuals in the index family 1. Affection of individuals varies in severity: II-4—meatal stenosis,
pollakisuria, and nycturia; III-2—urethral stenosis, surgically corrected, frequent UTI, pollakisuria, and nycturia; III-4—urethral
stenosis, frequent UTIs in youth, pollakisuria, and nycturia; IV-2—prenatal diagnosis in 13th week of gestation with megacystis, urethral
stenosis, surgically corrected and reconstructed. Individuals II-2 and I-2 are highlighted with the abbreviations E1 and E2 for unavailable
genetic and clinical evaluation and represent potential BNC2 carriers who did not participate in our study. Triangles denote miscarriages
and are annotated with respective weeks of gestation. E1 ¼ unavailable genetic evaluation; E2 ¼ unavailable clinical evaluation; and
Wk ¼ week of gestation.
(D) Ventral micturation cystourethrogram (MCUG) image of affected individual IV-2; family 1 shows severe bilateral VUR grade V.
(E) Pedigree with multiple affected individuals of family 2. Carriers of the identified BNC2 variant present with varying severity: I-2—no
history of UTI or high voiding frequency, normal renal ultrasound; II-1—pollakisuria, nycturia, and pathological MCUG; and II-1—
posterior urethral valve. I-2 is highlighted with a dot and represents a healthy carrier of the identified BNC2 variant.
(F) Oblique MCUG image of affected individual III-2; family 2 shows severe right VUR grade V.
998 The American Journal of Human Genetics 104, 994–1006, May 2, 2019
might interfere directly with the zinc finger domain’s ability
to bind to specific DNA sequences. Moreover, PROFAcc and
ISIS, implemented in the PredictProtein server,21,22 charac-
terize His888 as an exposed residue, located in a protein-
binding region. Because some C2H2 zinc-finger domains
were also shown to facilitate binding to proteins or RNA,23
the substitution p.His888Arg in BNC2 might affect not
only DNA, but also RNA, and/or might target protein bind-
ing. Because this novel variant has been transmitted from
anaffected father tohis affected son and because this variant
resides inahighlyconserved functional domainofBNC2,we
believe this variant to be possibly disease causing (Table 1).
Of the remaining three raremissense variants detected in
BNC2, the first variant, c.13G>A, detected in a boy with
PUV and severe dilatation of his upper urinary tract (vesi-
coureteral reflux [VUR]) and secondary ESRD, has been
reported in a heterozygous context six times (in two male
and four female carriers) in 124,816 alleles according to
gnomAD (allele frequency 0.000048). The GERP conserva-
tion score, the benign classification of three in silico
prediction programs, and the ACMG guidelines suggest
this variant to be benign. Parental DNA was not available
for testing of inheritance (Table 1, family 5). The second
rare missense variant, c.473C<T, detected in a male indi-
vidual with PUV, has been mentioned in a heterozygous
context three times (in one male and two female carriers)
in 245,826 alleles according to gnomAD (allele frequency
0.000012). This variant is highly conserved and predicted
by three in silico prediction programs to be disease causing.
Because the variant was transmitted from a father with un-
known affection status, we considered this variant to be a
variant of unknown clinical significance (Table 1, family
3). The third rare missense variant, c.1036G>C, was de-
tected in a male individual with PUV. It has been
mentioned only once in a heterozygous context (in one
male carrier) in 245,816 alleles according to gnomAD
(allele frequency 0.000004). Although the amino acid at
this position is highly conserved, only two out of three
in silico prediction programs classified the variant to be dis-
ease causing. Parental DNA was not available for testing of
inheritance (Table 1, family 4).
Hence, we classified the latter two missense variants,
c.473C>T and c.1036G>C, each residing at a highly
conserved amino acid position and predicted to be dis-
ease causing by at least two out of three in silico predic-
tion programs according to the ACMG guidelines, as
variants of unknown clinical significance. In addition
to these four missense variants, we detected four rare
(minor-allele frequency <0.0001) and two novel synony-
mous variants and one rare intronic variant (minor-allele
frequency <0.0001) within the direct vicinity to the
respective splice site (Table S2). The novel synonymous
variant c.1132A>C (p.Ser358Ser) was predicted by four
splice-site analysis programs to have an impact on
splicing at this side (Table S2). Nevertheless, it remains
speculative whether splicing is affected, and further
assessment of this variant is warranted.
Thereafter we sought to characterize the embryonic
effects on the contribution of BNC2 to the formation of
LUTO. BNC2 encodes a highly conserved zinc-finger
protein of poorly understood function. The Human Pro-
tein Atlas reports expression of BNC2 in the cytoplasm of
urothelial cells of the bladder. To study the expression of
BNC2 in the human urethra, we performed immunohisto-
chemistry staining with an anti-BNC2 antibody targeting
a region in the N-terminal-vicinity third zinc finger of
the canonical transcript ENST00000380672 (amino acids
(aa) 661-787) and ENST00000418777 (aa 618–743). In a
7-week human embryo (Figure 2), BNC2 expression was
detected in the urogenital sinus, the precursor of the
bladder, and its outflow tract. The most prominent
signal was in the primitive urothelium, and there was
weaker immunoreactivity in the surrounding mesen-
chyme (Figure 2 A–D). Expression was also detected in
the urothelium of the adult human male urethra
(Figure S3). We performed expression analysis by in situ hy-
bridization (ISH) in mouse embryos by using a pan-Bnc2
probe that showed Bnc2 expression in the developing
lower urinary-tract structures, with emphasis on the geni-
tal tubercle (gt) above the phallic urethra and below the
pelvic urethra at embryonic day (E) 13.5 (Figures 2E–2G),
the critical time point for urethral development. Expres-
sion of Bnc2was also visible in the brain, in themandibular
region, and in dorsal parts above the spinal cord. The
presence of the different Bnc2 mRNA (Bnc2-201 and
Bnc2-214) in the urogenital region of developing mouse
embryos was verified by Sanger sequencing. These mouse
mRNA represent the two different homologous human
transcripts that were found to be affected by the variants
identified in family 1 (ENST00000418777) and family 2
(ENST00000380672). Our expression data for Bnc2 during
murine development of the urinary tract and the existence
of a heterozygous Bnc2 knockout mouse, which was re-
ported by Bhoij et al.18 and presents with a cleft in the
ventral part of the external genitalia, support the impact
of BNC2 in urethral development. Furthermore, Bhoij
et al. describe homozygous knockout mice that have the
same defect but in a more penetrant and severe form.
These mice die soon after birth. Corresponding to that,
the Bnc2/ knockout mice, as described by Vanhoutte-
ghem et al., die soon after birth. Because of their cleft
palates and ingestion of air, these mice display aerial
distention of their digestive tracts and therefore have dis-
tended abdomens.24 The urinary tract was not examined
in these mice, although a distended abdomen is also
observed in human newborns with LUTO.25
In order to further investigate the function of BNC2
during urinary tract development, we used zebrafish as
a model organism. Their embryonic kidney, the pro-
nephros, consists of two nephrons, with a fused glomer-
ulus, two tubules, and ducts. The ducts terminate in a
cloaca, altogether reflecting a simplified model of the hu-
man nephron and urinary tract.26 BLAST analysis with
human BNC2 identified a single zebrafish bnc2 ortholog
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encoding six different transcripts. To study the expres-
sion of bnc2 in zebrafish larvae (zfl), we generated a
labeled RNA probe for ISH. We detected strong expres-
sion of bnc2 in the brain as described before27 but also
in the pronephric ducts and the developing cloaca region
at 33 hours post-fertilization (hpf) (Figure 2H). Expres-
sion of Bnc2 in the pronephric ducts was confirmed by
immunohistochemistry analysis in developing zfl at
100 hpf (Figure 2I, 2J).
Next, we performed phenotypic analysis after a Bnc2
knockdown indeveloping zfl.Wedesignedone specific anti-
senseMorpholino (MO), targeting the translation initiation
site of transcript bnc2_202 (ENSDART00000128671.4).
The canonical transcript in zebrafish bnc2_202 (ZFIN
and Ensembl genome browser) is the most similar to the
two human BNC2 transcripts that bear the discovered var-
iants (ENST00000380672 and ENST00000418777). The ze-
brafish protein shows an amino acid similarity of 85%,
similar protein structure, and a corresponding pattern of
zinc-finger domains. The shorter 110 kDa version
bnc2_201 (ENSDART00000102322.6) is, as predicted, not
targeted by the MO, as shown in the immunoblot analysis
(Figure 3A).
Injecting embryos with 0.75 ng of bnc2 MO caused a
distal pronephric outlet obstruction, which is illustrated
by a ‘‘vesicle’’ at the cloacal region. This ‘‘vesicle’’ was
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Figure 2. Embryonic Expression of BNC2 in Human, Murine, and Zebrafish Larvae Urinary-Tract Tissue
(A) H&E-stained transverse section through a 7-week human embryo at the level of the urogenital sinus (ugs): the hindgut (hg), meso-
nephric ducts (md), and ureters (u) are also indicated. H. sapiens ¼ Homo sapiens.
(B) Magnification of ugs, corresponding to the boxed region in (A), shows positive BCN2 immunoreactivity (brown) in the primitive
epithelium (arrowheads) and adjacent mesenchyme (asterisk).
(C) There is only a faint background signal in this adjacent section in which the primary antibody was omitted.
(D) Schematic overview depicting the human embryonic anatomy of the cross-section in (A). A red line indicates a sectional plane.
(E and F) ISH with a pan-Bnc2 probe on a sagittal section of a representative E13.5 (TS21) mouse embryo.
(E) Bnc2 expression is visible (in blue) in the brain, in themandibular region, and in a small patch at the dorsal side above the spinal cord
(white arrowheads top to bottom). Specific expression is furthermore observed in the urogenital region (black arrowheads).
(F) Magnification (square in E) of the same embryo. Cells that express Bnc2 are found in the gt above the phallic urethra (phur) and below
the pelvic urethra (plur) (black arrowheads). M. musculus ¼ Mus musculus; pbl ¼ primitive bladder
(G) Schematic overview depicting the embryonic mouse anatomy of the cross-section in E.39
(H) Whole-mount ISH with an anti bnc2 probe shows (in purple) the expression of bnc2 RNA at 33 hpf in the pronephric ducts in WT
zfl. In the lateral view (top), the pronephric duct is located above the yolk extension (black arrowheads), and in the dorsal view (bot-
tom), the pairwise anlage of pronephric ducts are positively labeled. Sense controls (ctrl) did not show a staining. D. rerio ¼ Danio rerio.
(I) Immunohistochemistry staining (in brown) against Bnc2 on a sagittal paraffin cross-section of WT zebrafish at 100 hpf indicates
Bnc2-positive cells in the pronephric duct (black arrowheads) but not in the intestine (black asterisk).
(J) Schematic overview of pseudo-colored cloacal region of a 4 dpf zfl for better orientation and identification (modified according to
Pyati et al.).33 K ¼ kidney (red); G ¼ gut (green); and C ¼ cloaca (yellow).
Scale bars represent 80 mm (A), 20 mm (B–C), 2 mm (E), 600 mm (F), 500 mm (H), and 100 mm (I)
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Figure 3. Depletion of Bnc2 Causes Pericardial Effusion, Hydrocephalus, Glomerular Cysts, and Distal Pronephric-Outlet Obstruction
in Zebrafish
(A) Immunoblot analysis shows a protein decrease in bnc2MO-injected zfl for Bnc2-202 (130 kDa, C7DZJ6 according to UniProt ID) but
not for Bnc2-201 (110 kDa, F1R42 according to UniProt ID) at 2 days dpf, which is as predicted for the specific MO target side. UI ¼
uninjected.
(B) H&E staining of a sagittal section of a MO-injected zfl (lateral view, head to the left) shows (PE), hydrocephalus (HY), abnormal body
curvature and a ‘‘vesicle’’ due to an outlet obstruction of the pronephric ducts (arrowhead in enlargement in B) at 56 hpf.
(C) Zfl injected with bnc2MO frequently develop a distal-outlet obstruction at 33 hpf; this obstruction is highlighted by an arrowhead in
the enlargement of (C).
(D) Whole-mount ISH with a pax2a probe relates the constituent parts of the bnc2 MO-induced pronephric-outlet obstruction to distal
parts of the pronephric ducts and the cloacal region (black arrow).
(legend continued on next page)
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detected in approximately 21% of bnc2MO-injected larvae
at 33 hpf (n ¼ 399) but in 0% in controls (n ¼ 500,
p ¼ 0.0001 [unpaired t test]); these results resemble those
for the anatomical blockage found in the human individ-
uals with LUTO (Figures 3B, 3C, and 3H).
Besides this strikingly specific phenotype, the bnc2
MO-injected zfl showed additional phenotypes such as
abnormal body curvature (9%), hydrocephalus (HY) (5%),
and pericardial effusion (PE) (44%). PE is sometimes consid-
ered to be nonspecific and is also seen in wild-type (WT)
fish.28 However, because of the high number of bnc2 MO-
injected zfl with PE, one might speculate that PE represents
a secondary effect of kidney impairment. This has been
described before in MO zebrafish experiments for mono-
genic nephrotic syndrome.29 A previous study by Ogura
et al. has shownabnormalbodycurvature in zfloverexpress-
ing human BNC2; this abnormal curvature corresponds to a
multifactorial etiology of human scoliosis.30 The etiology of
HY remains elusive; a relation to the pronephric defect
seems unlikely.
To further study the involvement of Bnc2 in formation
of the distal pronephric outlet obstruction, or dilatation,
in the cloacal region (inlays in Figures 3B and 3C), we per-
formed ISH in bnc2MO-injected zfl. A probe against pax2a,
a marker for pronephric and cloacal tissue, indicated the
intimate relation of the pronephric-outlet obstruction
with the distal pronephric duct at the cloacal opening
(Figure 3D). Because this MO only targets translation into
Bnc2 protein and the expression of bnc2 mRNA should
not be altered, we could demonstrate bnc2 expression over-
lapping with pax2a in the region of the pronephric-outlet
obstruction (Figures 3D and 3E).
To assess the impact of the Bnc2 knockdown on the
proximal pronephric ducts and the glomeruli, we used a
transgenic Tg(wt1b:GFP) reporter fish, showing GFP expres-
sion in these tissues.31 bnc2 MO-injected Tg(wt1b:GFP) zfl
demonstrated pronephric cysts at 54 hpf in 57% of survi-
vors (n¼ 47) (Figures 3F–3G and 3J) but in 6.5% in controls
(n ¼ 77, p ¼ 0.0067 [unpaired t test]). These cysts occur
at the transition between neck and proximal convoluted
tubule of the pronephric nephron. The formation of the
pronephric cysts and dilated ducts is consistent with our
hypothesis that a reduction of Bnc2 in zebrafish causes
mechanical cloacal obstruction.
To demonstrate the specificity of theMOknockdown,we
performedmRNA rescue experiments. Co-injection of bnc2
MO together with human BNC2 WT mRNA (transcript
ENST00000380672, family 2) did not result in a reduction
of the general mortality caused by the MO, but it could
significantly rescue the LUTO-specific pronephric-outlet
obstruction (Figures 3I and 3J) and furthermore reduce
the MO-induced cysts in the Tg(wt1b:GFP) zfl (Figure 3H).
To further prove the specificity of the observed LUTO-like
phenotypes, we generated an independent transient
CRISPR/Cas approach in which we designed single guide
RNA (sgRNA) targeting different genomic positions in
bnc2. sgRNA-6-injected zfl developed pronephric-foutlet
obstruction similar to that developed by the bnc2 MO-in-
jected zfl at a rate of 5%at 33hpf (n¼ 103) (Figure S4). Addi-
tionally, transient CRISPR/Cas Bnc2 knockdown larvae
showed slight body curvature and HY for sgRNA 4 at
2 days post-fertilization (dpf) and a generally reduced sur-
vival rate similar to that of the bnc2 MO zfl (Figure S4).
This strongly suggested that the observed zebrafish pheno-
types were caused by Bnc2 knockdown after administering
bnc2 MOs. Previously Lang et al., in an ENU-mutagenesis
model, were able to show that bnc2/KO zfl present with
HY and adult zebrafish present with disturbed pigmenta-
tion.27 In their study, the authors did not investigate their
bnc2/KO zfl for anomalies of the pronephric ducts or
the cloacal region.
To assess the impact of the discovered alleles in BNC2,
we compared two of these variants in the same MO rescue
approach as described above but co-injected mRNA car-
rying the respective variants instead of WT mRNA. Co-in-
jection of human BNC2 mRNA bearing the p.His888Arg
variant of family 2 did not result in a rescue of the pro-
nephric outlet obstruction as observed with the WT
mRNA (ENST00000380672) (Figure 3H). Consistently, co-
injection of the same p.His888Arg BNC2 mRNA failed to
(E) ISH with a bnc2 probe in bnc2 MO-injected embryos shows bnc2 mRNA expression in relevant tissues forming a pronephric-outlet
obstruction (black arrow).
(F and G) Zfl injected with bnc2 MO develop glomerular cysts (white arrowheads in G) and dilatation of the pronephric ducts (white
asterisk in G). Images from in vivo observation through fluorescence microscopy (dorsal view) in Tg(wt1b:GFP) were taken at 54 hpf
in zfl injected with control (Ctrl) MO (F) and bnc2 MO (G). Tg ¼ transgenic zebrafish line.
(H) The graph shows100%of all at 1 dpf surviving zflof the five different cohorts: UI, CtrlMO, bnc2MO, bnc2MOþWThumanRNA, and
bnc2MOþmutatedhumanRNA (transcript ENST00000380672) bearing the p.His888Arg variant (for absolute numbers, see Figure 3H). A
distal ‘‘vesicle’’ due to an outlet obstruction (phenotype) of the pronephric ducts can be seen in 21% of bnc2MO-injected zfl compared to
0%of zflwitha ‘‘vesicle’’ inbothcontrol groups (p<0.05,unpaired t test). 6%of zfl injectedwithbnc2MOþWTmRNAdevelopa ‘‘vesicle,’’
and so do 16% of zfl injected with bnc2MO þ p.H888R. Data are presented as means with standard error of the mean (SEM).
(I) Quantification of glomerular cyst rates (phenotype) in Tg(wt1b:GFP) zfl at 2 dpf depicts significantly (p < 0.05, unpaired t test) clear
glomerular cysts in 57% of bnc2 MO-injected zfl. 26% of zfl injected with bnc2 MO þWT RNA develop pronephric cysts; 51% of those
injected with bnc2 MO þ p.His888Arg RNA develop pronephric cysts. Data are presented as means with SEM.
(J) Quantification of death rates at up to 3 dpf shows an increased mortality up to 64% in bnc2MO-injected zfl compared to zfl injected
with UI (7%) and Ctrl MO (6%). With bnc2 MO injected, zfl show significantly (p < 0.0001, Mantel-Cox test) reduced survival. Co-in-
jection of bnc2MO þ humanWT RNA results in a mortality of 69%. Aggravated mortality up to 81% can be detected in the zfl injected
with bnc2 MO þ p.His888Arg RNA.
Scale bars represent 200 mm (B), 50 mm (magnification in B), 500 mm (C), 100 mm (magnification in C), and 100 mm (D–G). **p < 0.005,
*** p < 0.0005.
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rescue the bnc2-MO-induced pronephric cysts in the
Tg(wt1b:GFP) zfl (Figure 3I).
For the rescue experiments regarding the BNC2 tran-
script ENST00000418777 affected in family 1, we observed
a tendency toward a decrease of the distal pronephric-
outlet obstruction. Co-injection of BNC2 bearing the
p.Arg853* variant showed no reduction of the specific
phenotype (Figure S5).
The Bnc2 knockdown resulted in significantly reduced
survival of zfl within 3 dpf (control [Ctrl] MO 94% versus
bnc2 MO 36%) (Figure 3J). Although the co-injection of
human WT BNC2 mRNA did not reduce mortality
compared to that seen with solely bnc2 MO injection
(bnc2 MO þ WT RNA 69% [ENST00000380672]; bnc2
MO þWT RNA 63% [ENST00000418777]), we observed a
slightly aggravated mortality in zfl co-injected with
mutated BNC2 mRNA (bnc2 MO þ p.His888Arg RNA
81% [ENST00000380672]; bnc2 MO þ p.Arg853* RNA
88% [ENST00000418777]). We hypothesize several expla-
nations for the failed rescue of mortality: general toxicity
of mRNA, ubiquitous unregulated expression of BNC2,
and the use of orthologous humanmRNA in the zfl model.
The distal pronephric-outlet obstruction is a very specific
phenotype resembling the human LUTO phenotype, and
because this obstruction can be rescued by human WT
but not by mutated BNC2 mRNA, the data clearly demon-
strate the role of BNC2 variants in LUTO.
We also employed an acute multi-sgRNA (mgRNA)
approach targeting different positions in bnc2. This
mgRNA resulted in median likelihoods of>99% for at least
one variant on each allele deletion profiles, which were
analyzed with the ICE synthego tool. We observed signifi-
cantly reduced survival (50% median survival at 7 dpf) in
zfl injected with bnc2 mgRNA (sgRNA 2, 6, and 8) over a
time period of 21 dpf in comparison to zfl injected with
scrambled sgRNA (Ctrl) and uninjected larvae (UI) and
40% survival at the end of the experiment (Figure S1E). A
distal-outlet obstruction of the pronephric ducts was de-
tected in 3% of bnc2-mgRNA-injected embryos at 33 hpf
(n ¼ 35).
Our hypothesis that the ‘‘cloacal vesicle’’ is derived from
pronephric tissue and represents a pronephric-outlet
obstruction at the cloacal opening was supported by bnc2
knockdown in the mnr2b/hlxb9lb enhancer trap line
Tg(HGj4A), which expresses GFP in the pronephric ducts
during development.32 Expression of GFP in cells lining
the inner wall of the MO-induced pronephric-outlet
obstruction clearly demonstrated that they belong to the
distal pronephric duct (Figure 4A). High-resolution 3D
stack imaging not only showed the connection of the pro-
nephric ducts to the pronephric outlet obstruction but also
exhibited dilatation of the distal part of the pronephric
ducts (Figures 4B–4D). This finding is consistent with the
observed dilatation of the proximal pronephric duct in
the Tg(wt1b:GFP) line (Figure 3G, asterisks). Injecting a
cell tracer dye, CellTracker Red CMTPX, into the proneph-
ric-outlet obstruction at 33 hpf showed that the cells
forming the ‘‘vesicle’’ become part of the distal pronephric
duct and cloaca later in development (56 hpf and 74 hpf)
as the pronephric-outlet obstruction eventually ‘‘ruptures’’
between 36 and 40 hpf (Figure S6).
In zebrafish, formation of the cloaca and opening occurs
around 24–30 hpf through programmed cell death of
epidermal cells.33,34 Thus, we speculated that Bnc2, poten-
tially acting as a transcription factor, controls the cell fate of
the cloacal andpronephric-duct cells. Performing immuno-
histochemistry staining analysis with an anti-cleaved cas-
pase 3 antibody, we detected a higher rate of apoptosis
around the cloacal region and distal pronephric duct in
bnc2MO zebrafish at 1 dpf and 2 dpf, suggesting that bnc2
affects programmed cell death and leads to increased
apoptosis (Figures 4E–G). One might speculate that the
pronephric-outlet obstruction is causing retention of urine
and that the resulting higher pressure in the pronephric
ducts secondarily damages pronephric nephron cells and
possibly the glomerular tissue and ultimately leads to cystic
dilatation. However, the exact mechanism leading to the
cloacal anomalies in bnc2MO-injected zfl remains elusive.
Several phenotypic features observed in bnc2 MO-in-
jected zfl (e.g., HY and cystic alterations of the kidneys)
resemble features of the ciliopathy disease spectrum. Cells
forming the pronephric duct normally exhibit multiple
cilia that propel excreted urine toward the cloaca. There-
fore, we were interested in determining whether cilia are
morphologically altered in our knockdown morphants.
Using immunofluorescence staining against acetylated
tubulin and GFP in Tg(wt1b:GFP) zfl, we observed normal
cilia morphology, but we also observed dilatation of the
pronephric duct as observed previously in bnc2 MO zfl at
56 hpf (Figures 4H and 4I).
Hence, after a Bnc2 knockdown in zfl, we observed
phenotypic features resembling the human phenotypic
LUTO spectrum. The pronephric-outlet obstruction re-
flects the anatomical blockage of human PUVs or urethral
stenosis that leads to urine retention and consecutively to
dilatation of proximal parts of the nephron. This dilatation
could be demonstrated through the use of two transgenic
lines. The pronephric cysts might resemble the kidney
damage observed in human individuals with LUTO; such
individuals often suffer from early-onset renal failure
despite proper urine drain management.35
To assess the impact of the discovered variants
p.His888Arg (family 2) and p.Arg853* (family 1), we per-
formed mRNA rescue experiments. Co-injection of bnc2
MO and human WT mRNA resulted in a reduction of the
LUTO-specific phenotype, which could not be rescued by
the respective mutated BNC2 mRNA (Figure 3H–I,
Figure S5). Thereby, we provided strong evidence for a
pathogenic effect for the BNC2 variants found in our index
families (families 1 and 2).
The phenotypic spectrum of human LUTO phenotypes
is broad and has displays interfamilial variability. Because
milder forms canmanifest at older ages, it must be assumed
that within large control databases such as gnomAD, some
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individuals with a particular disease-causing variant or ge-
notype fail to express most if not all features of the disease
in question. This phenomenon is known as ‘‘reduced (or
incomplete) penetrance.’’36 Reduced penetrance is not
uncommon; indeed, there are many known examples of
‘‘disease-causing variants’’ that fail to cause disease in a pro-
portion of their carriers. As one example of such genes,
HNF1B can be mentioned. Here, besides a variable pheno-
type even within families carrying the same variant, appar-
ently unaffected family members could also be found to
carry variants.37 Reduced penetrance might therefore
explain not only why monogenic diseases are occasionally
transmitted through unaffected parents but also why
healthy individuals can harbor quite large numbers of
potentially disadvantageous variants in their genomes
without suffering any clinically obvious phenotypes.
Reduced penetrance can be a function of the specific vari-
ant(s) involved or of allele dosage.38 It might also result
from differential allelic expression, copy-number variation,
or the modulating influence of independent genetic vari-
ants. The penetrance of some pathogenic genotypes is
known to be age- and/or sex-dependent. Variable pene-
trance might also reflect the action of unlinked modifier
genes, epigenetic changes, or environmental factors. Sup-
porting this observation of incomplete penetrance in
humans, our bnc2 MO and CRISPR knockdown fish show
a phenotypic spectrum ranging from pronephric cysts in
57% (in bnc2 MO) to a visible pronephric-outlet obstruc-
tion (‘‘vesicle’’) in 21% and 3%, respectively. Because
PUVs, the most common human LUTO phenotype, are
limited tomales, one would expect to find a higher number
of female thanmale carriers formonoallelic disease-causing
variants among healthy control individuals. This circum-
stance might in part explain why all heterozygous carriers
(n ¼ 5) reported in gnomAD for the truncating variant
p.Arg853* identified in our family 1 are females.
Functional studies in mouse embryos and our zfl studies
now show that BNC2 plays an important role in early
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Figure 4. Distal Pronephric-Outlet
Obstruction Is Formed by Pronephric Tis-
sue and Causes Dilated Pronephric Ducts
and Increased Apoptosis
(A) Tg(HGj4A) GFP-reporter zfl (lateral view)
injected with bnc2 MO emphasize the
belonging of the distal pronephric-outlet
obstruction, visible as a ‘‘vesicle’’ (marked
with a white asterisk), to the distal proneph-
ric duct and cloaca. The enlarged inlay shows
the same ‘‘vesicle’’ in the sole bright-field
image.
(B and C) High-resolution two-photon mi-
croscopy dorsal view of the cloacal region
(white asterisks) in Tg(HGj4A) zfl injected
with Ctrl MO (B) and bnc2MO (C) indicates
the intimate relation of the pronephric-
outlet obstruction to the bilateral proneph-
ric ducts. Widths of the pronephric-duct
lumen are indicated with white arrows.
(D) Quantification of pronephric-duct
widths in Tg(HGj4A) zfl injected with bnc2
MO shows significantly (p ¼ 0.0002, Stu-
dent’s t test) dilated pronephric ducts
compared to controls. PD ¼ pronephric
ducts.Data arepresentedasmeanswithSEM.
(E–G)Cleaved caspase 3 staining in bnc2MO-
injectedzfl(56hpf) showsanincreased rateof
apoptosis (black arrowheads in G) compared
to Ctrl MO-injected embryos (E–F) around
the pronephric duct (marked by red lines),
the cloacal region, and the central nervous
system (not shown). An overview empha-
sizing and localizing the pronephric regions
shown in (F) and (G) is shown inV.
(H and I) Dorsal image from immunofluores-
cence staining of acetylated tubulin-stained
cilia (red, acetTub) and GFP (green) depicts
normal cilia morphology in the pronephric
ducts in Tg(wt1b:GFP) zfl injected with Ctrl
MO(H) andbnc2MO(I) at 56hpf. Pronephric
ducts are widened in the bnc2 MO zfl as
mentionedbefore.White arrowheadspoint toglomerularcysts inthebnc2MOzfl.Thesoleacetylated-tubulinstain (redchannel) emphasizes
cilia morphology in the respective enlargement inlays of (H) and (I).
Scale bars represent 200 mm(A), 50mm(magnification ofA–C), 100 mm(E–G), 50mm(Hand I), and25mm(magnifications ofH and I). *** p<
0.0005.
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urinary-tract development across different species and sug-
gest that bnc2 deficiency in zfl causes pronephric-outlet
obstruction and cystic anomalies of the pronephros and
thereby phenocopies human LUTO. In conclusion, here
we present evidence that monoallelic variants in BNC2,
coding for basonuclin 2, are strongly implicated in human
LUTO with anatomical blockage of the urethra.
Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.03.023.
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